Cargando…

The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non‐small cell lung cancer treated with immune checkpoint inhibitors

BACKGROUND: Preclinical data have shown the immunomodulatory effects of metformin and dipeptidyl peptidase 4 (DPP4) inhibitors in patients with diabetes. However, its clinical impact remains unclear in lung cancer. METHODS: Between 2017 and 2021, 466 patients received ICI monotherapy. Patients were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jieun, Kim, Se Hyun, Jung, Eun Hee, Kim, Sang‐A, Suh, Koung Jin, Lee, Ji Yun, Kim, Ji‐Won, Kim, Jin Won, Lee, Jeong‐Ok, Kim, Yu Jung, Lee, Keun‐Wook, Kim, Jee Hyun, Bang, Soo‐Mee, Lee, Jong Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807448/ https://www.ncbi.nlm.nih.gov/pubmed/36351567 http://dx.doi.org/10.1111/1759-7714.14711

Ejemplares similares

Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
por: Kim, Kyoung Jin, et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
por: Rhee, Su-jin, et al.
Publicado: (2016)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Kim, Mi-Jin, et al.
Publicado: (2020)

R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience
por: Lee, Ji Yun, et al.
Publicado: (2021)

A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study
por: Choi, In Sil, et al.
Publicado: (2018)

Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
por: Lee, Sook Jung, et al.
Publicado: (2019)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
por: Seong, Jong-Mi, et al.
Publicado: (2021)

Renoprotective Effect of a Dipeptidyl Peptidase-4 Inhibitor on Aging Mice
por: Ban, Tae H, et al.
Publicado: (2019)

Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study
por: Kang, Minsu, et al.
Publicado: (2022)

PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer
por: Kim, Kui-Jin, et al.
Publicado: (2020)

Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
por: Shin, Junghoon, et al.
Publicado: (2019)

Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
por: Bae, Jaehyun, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation
por: Lee, Choon-Soo, et al.
Publicado: (2016)

Acute pulmonary thromboembolism caused by factor V Leiden mutation in South Korea: A case report
por: Choe, Hun Jee, et al.
Publicado: (2019)

Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database
por: Suh, Sunghwan, et al.
Publicado: (2015)

Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
por: Kwon, Ji-Hyun, et al.
Publicado: (2019)

Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study
por: Choi, In Sil, et al.
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study
por: Kim, Young-Gun, et al.
Publicado: (2018)

Identification of a potentially avoidable cardiopulmonary resuscitation in hematology and oncology wards
por: Choi, Yeonjoo, et al.
Publicado: (2019)

Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
por: Ha, Kyoung Hwa, et al.
Publicado: (2018)

Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients
por: Park, Hyo Eun, et al.
Publicado: (2015)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
por: Kim, Kwang-il
Publicado: (2018)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Health in Patients with Type 2 Diabetes Mellitus
por: Lee, Dong-Hwa, et al.
Publicado: (2021)

Dipeptidyl Peptidase 10, a Novel Prognostic Marker in Colorectal Cancer
por: Park, Heae Surng, et al.
Publicado: (2013)

Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
por: Jung, Gwon-Soo, et al.
Publicado: (2016)

Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study
por: Lee, Kyung Ae, et al.
Publicado: (2022)

Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation
por: Seo, Songyi, et al.
Publicado: (2020)

Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
por: Kim, Sang-A, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study
por: Chung, Yoo-Ri, et al.
Publicado: (2019)

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
por: Lee, Jung Min, et al.
Publicado: (2019)

Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes
por: Oh, Tae Jung, et al.
Publicado: (2013)

Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report
por: Kim, Hae Jin, et al.
Publicado: (2019)

Constituents of Coreopsis lanceolata Flower and Their Dipeptidyl Peptidase IV Inhibitory Effects
por: Kim, Bo-Ram, et al.
Publicado: (2020)

PI3K p110α Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells
por: Lee, Hyun Jung, et al.
Publicado: (2020)

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
por: Kim, Ye An, et al.
Publicado: (2015)

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus
por: Choi, Yeo Jin, et al.
Publicado: (2019)

Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
por: Oh, Ju Hee, et al.
Publicado: (2022)

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney
por: Joo, Kwon Wook, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_r6icjeqv60ldrrhmbpguqskv1r